BioSig Technologies, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by BioSig Technologies, Inc. (not Streamex Corp.) on September 5, 2014, covering events occurring on September 1, 2014. The filing details material agreements regarding debt cancellation, equity compensation, and board appointments.
Key Financial Metrics and Agreements
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity figures. Instead, it reports the following specific financial transactions:
- Debt Cancellation: The Company extinguished a repayment obligation owed to Dr. Asher Holzer (Board Member) for services under a 2012 consulting agreement.
- Equity Grants (Options):
- Dr. Asher Holzer: Granted 75,000 nonstatutory stock options at an exercise price of $2.50/share (100% vested immediately).
- Patrick Gallagher (New Director): Granted 150,000 nonstatutory stock options at an exercise price of $2.50/share (50% vested at grant, remainder vesting over 1 year).
- Equity Grants (Restricted Stock):
- Kenneth Londoner (Executive Chairman): Granted 400,000 shares of restricted stock (100% vested immediately).
- Steve Chaussy (CFO): Granted 200,000 shares of restricted stock (100% vested immediately).
Material Changes
The primary material change is the settlement of a liability (Repayment Obligation) to Dr. Holzer in exchange for equity, effectively converting a debt obligation into a stock option grant. Additionally, the Company expanded its board with the appointment of Patrick Gallagher and issued significant equity awards to executive leadership.
Outlook, Risks, and Management Commentary
The filing contains no forward-looking guidance, revenue outlook, or specific risk factors beyond the standard terms of the equity incentive plan. The Company notes that the summary of the Cancellation and Release Agreement is qualified by the full text of the agreement attached as Exhibit 10.1.
Key Facts for Investor Verification
- Verify the total value of the "Repayment Obligation" cancelled for Dr. Holzer to assess the impact on prior liabilities.
- Confirm the dilution impact of the 925,000 total shares/options granted on September 1, 2014 (75k Holzer, 150k Gallagher, 400k Londoner, 200k Chaussy).
- Review the vesting schedules for Patrick Gallagher's options to understand future compensation obligations.
- Check the Company's 2012 Equity Incentive Plan to ensure sufficient shares were available for these grants.